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 Risk Score for Predicting Outcome in Patients With
Asymptomatic Aortic Stenosis
Jean-Luc Monin, MD, PhD; Patrizio Lancellotti, MD, PhD; Mehran Monchi, MD; Pascal Lim, MD;
Emmanuel Weiss, MD; Luc Piérard, MD, PhD; Pascal Guéret, MD
Background—The management of patients with asymptomatic severe aortic stenosis remains controversial. We sought to
develop a continuous risk score for predicting the midterm development of symptoms or adverse events in this setting.
Methods and Results—We prospectively followed 107 patients with asymptomatic aortic stenosis (aged 72 years [63 to
77]; 35 women; aortic-jet velocity, 4.1 m/s [3.5 to 4.4]) at a single center in France. Predefined end points for assessing
outcome were the occurrence within 24 months of death or aortic valve replacement necessitated by symptoms or by
a positive exercise test. Variables independently associated with outcome were used to build a score that was validated
in an independent cohort of 107 patients from Belgium. Independent predictors of outcome were female sex, peak
aortic-jet velocity, and B-type natriuretic peptide at baseline. Accordingly, the score could be calculated as follows:
Score[peak velocity (m/s)2](natural logarithm of B-type natriuretic peptide1.5)1.5 (if female sex). Event-free
survival after 20 months was 80% for patients within the first score quartile compared with only 7% for the fourth
quartile. Areas under the receiver operating characteristic curve for the score were 0.90 and 0.89 in the development and
validation cohorts, respectively.
Conclusions—If further validation is achieved, this score may be useful to predict outcome in individual patients with
asymptomatic aortic stenosis to select those who might benefit from early surgery. (Circulation. 2009;120:69-75.)
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A
ccording to current guidelines, severe symptomatic aor-
tic stenosis (AS) is a straightforward indication for valve
replacement.1,2 In contrast, the decision to operate on asymp-
tomatic patients remains a source of debate.1,2 The risk of
sudden death without preceding symptoms remains a matter
of concern,3 as well as the risk of irreversible myocardial
damage due to left ventricular (LV) hypertrophy.4 Further-
more, the potential for rapid disease progression and excess
mortality in patients with even moderate AS has been pointed
out recently.5 Prospective studies have demonstrated the poor
midterm outcome of asymptomatic patients with high peak
aortic-jet velocity at baseline6 or moderate to severe valve
calcification.7 The prognostic value of B-type natriuretic
peptide (BNP) serum level, reflecting LV end-systolic wall
stress, has also been evaluated.8–12 However, no single value
is an absolute criterion to define hemodynamic severity or to
predict the development of symptoms because functional
capacity in AS is the result of a complex interplay between
the aortic valve, the LV, and the systemic vasculature.13 Thus,
to select the patients who are likely to benefit from early
surgery, a continuous score integrating valve and ventricular-
related parameters might be more appropriate. Therefore, we
prospectively followed 107 asymptomatic patients with mod-
erate to severe AS at a single center in France. Independent
predictors of outcome were integrated to build a continuous
risk score, designed to predict the midterm development of
symptoms or other adverse events. This score was then
validated in an independent set of 107 patients from Belgium.
Editorial see p 9
Clinical Perspective on p 75
Methods
Patients
The development cohort consisted of 107 consecutive patients
referred to the Echocardiography Laboratory at Henri Mondor
University Hospital (Créteil, France) and prospectively enrolled on
the basis of the following criteria: (1) moderate to severe AS,
defined1 by a peak aortic-jet velocity 3.0 m/s and/or aortic valve
area 1.5 cm
2; (2) absence of symptoms; (3) normal LV function
defined by an ejection fraction 50% without segmental wall motion
abnormality by echocardiography; (4) normal sinus rhythm; (5) no
more than mild associated cardiac valve lesion; and (6) serum
creatinine 160 mol/L. The validation cohort included 107 con-
secutive patients with asymptomatic AS, who were prospectively
followed at Sart Tilman University Hospital (Liège, Belgium). Both
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  centers used the same inclusion criteria, the same protocol for
echocardiographic and BNP measurements, and the same indications
for valve replacement according to current guidelines.2 This study was
approved by both local institutional ethics committees, and written
informed consent was obtained from all patients before enrollment.
Echocardiography
Comprehensive Doppler echocardiography, including M-mode,
2-dimensional echocardiography, color Doppler, and pulsed-wave
and continuous-wave Doppler measurements, was performed in all
patients at baseline and at each follow-up visit. Patients in the
development cohort were evaluated mainly by a single senior
echocardiographer (J.-L.M.; 90% of examinations) with the use of
commercially available systems. In 17 patients, the baseline echo-
cardiography was repeated by the same physician after 25 (18 to 37)
days. Thus, intraobserver variability was as follows (meanSD): LV
outflow tract diameter, 0.10.5 mm; LV outflow tract time-velocity
integral, 03 cm; peak aortic-jet velocity, 0.00.3 m/s; mean
transaortic pressure gradient, 16 mm Hg; and aortic valve area,
0.010.09 cm
2. The suspected origin of AS was determined accord-
ing to current criteria.7 Peak aortic-jet velocity was derived from
transaortic flow, recorded with continuous-wave Doppler with a
multiwindow approach.6 Aortic valve area was calculated by the
continuity equation14 and indexed to body surface area. The degree
of aortic valve calcification was assessed from echocardiographic
zoomed short-axis views and scored on a 4-grade scale according to
Rosenhek et al.7
Exercise Testing
Symptom-limited graded bicycle exercise tests were performed at
inclusion in 89 patients (83%) of the development cohort. After an
initial workload of 25 W maintained for 2 minutes, the load was
increased by steps of 25 W every 2 minutes. Twelve-lead ECG was
monitored continuously and recorded every 2 minutes with blood
pressure measurements. The exercise test was considered abnormal
if any of the following events occurred during exercise: dyspnea,
angina, syncope or near syncope; insufficient rise in systolic blood
pressure (20 mm Hg) or fall in blood pressure compared with
baseline; 80% of the normal level of exercise tolerance according
to age- and sex-adjusted levels; 2 mm horizontal or downsloping
ST-segment depression compared with rest; ventricular tachycardia
or 4 premature ventricular complexes in a row.15
BNP Measurements
Venous blood samples for BNP were drawn before echocardiogra-
phy or any exercise test after 20 minutes of supine rest. Chilled
ethylenediaminetetra-acetic acid tubes were centrifuged immediately
at 4000g (4°C) for 15 minutes. Separated plasma samples were
processed by immunofluorescence assay (Beckman-Coulter, Bio-
site). The interassay and intra-assay variations were 5% and 4%,
respectively. The assay detection limit was 1 pg/mL.
Follow-Up
Follow-up visits were scheduled every 6 to12 months, according to
guidelines.1,2 Each visit included a clinical evaluation, BNP mea-
surements, Doppler echocardiography, and exercise testing (if indi-
cated and applicable). Valve replacement was indicated according to
current guidelines (ie, occurrence of symptoms or abnormal exercise
test [symptoms or abnormal blood pressure response during exer-
cise]).2 Predefined end points for assessing outcome in the develop-
ment cohort were the occurrence within 24 months after enrollment
of death (any cause) or aortic valve replacement necessitated by
symptoms or by a positive exercise test.2 We chose a 24-month
period because it seemed to be the shortest clinically relevant interval
for delaying surgery according to a “wait-for-symptom” strategy.
Statistical Analysis
Descriptive data are reported as proportions for qualitative variables
and median (quartile 1 to quartile 3) for continuous variables, unless
otherwise indicated. In the development cohort, baseline variables
previously described as associated with outcome (age,7 sex,16 cause
of AS and calcification score,7 peak velocity, mean transaortic
pressure gradient and valve area,3,6 and BNP serum level8,10,11) were
screened for association with the 24-month end point. We used 
2
tests for categorical data. To assess the relationship between each
numerical variable and the 24-month end point, we first plotted
continuous variables against the 24-month end point, and we used
the Lowess smoothing function with locally weighted least squares
to identify proportional relationships. The results of this procedure
indicated that for BNP, a natural logarithm transformation is needed
for proportionality. The associations linking numerical variables to
the 24-month end point were evaluated by Mann-Whitney U tests. P
values 0.05 were considered statistically significant. All statistical
tests were 2-tailed.
Variables significantly associated with outcome in univariable
analysis were included in a multiple logistic regression model.17–19
We used backward elimination of nonsignificant variables to define
a simple score. Then the  coefficient of each of the variables
independently associated with a 24-month end point was used to
build the score.20
Finally, we evaluated the score performance to predict the 24-
month composite end point in the development cohort and an
independent validation cohort of 107 patients. To evaluate discrim-
ination, the area under the receiver operating characteristic curve was
determined.21 To evaluate calibration, Hosmer-Lemeshow goodness-
of-fit tests using 5 quintiles of poor outcome were performed.
Results
Characteristics and Outcomes in the
Development Cohort
In the development cohort, follow-up information was avail-
able for 104 patients (97%). On the basis of patient history
and echocardiographic analysis, the suspected origin of AS
was calcification of a 3-leaflet (n75), bicuspid (n22), or
unicuspid (n1) aortic valve, rheumatic disease (n2),
radiotherapy (n2), or undetermined (n2). According to
current guidelines, AS was severe or moderate in 75 and 29
patients, respectively. Predefined end points were reached in
62 patients within 8 months (5 to 13) including 3 deaths, 58
aortic valve replacements, and 1 patient who refused surgery
despite development of symptoms and a positive exercise
test. Of note, 90% of outcomes in this group (n56) occurred
before 20 months. One patient died postoperatively (operative
mortality, 2%) at day 4 from right ventricular failure. In
contrast, 42 patients remained free of clinical event after 32
months (26 to 45) of follow-up. Patients’ characteristics
according to outcome are given in Table 1.
Deaths Before Surgery
Three patients from the development cohort died before
surgery. A 79-year-old man with moderate AS (peak velocity,
3.9 m/s; aortic valve area, 1.1 cm
2; BNP, 245 pg/mL) died of
pneumonia after 6 months. A 75-year-old woman with severe
AS (peak velocity, 4.6 m/s; aortic valve area, 0.7 cm
2; BNP,
56 pg/mL) died of bowel cancer at 10 months. A 71-year-old
man with moderate AS (peak velocity, 3.5 m/s; aortic valve
area, 1.2 cm
2; BNP, 34 pg/mL) died of aortic endocarditis at
14 months.
Valve Replacement Indicated by Exercise
Test Results
Valve replacement was indicated for an abnormal exercise
test at baseline in 11 patients (aged 76 years [70 to 78]; peak
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 velocity, 4.1 m/s [3.7 to 4.5]; BNP, 175 pg/mL [62 to 240]).
These tests were considered positive for dyspnea (n3), fall
of systolic blood pressure (n4), or insufficient rise in blood
pressure (n4, associated with significant ST depression in 2
cases). These 11 patients underwent surgery within 2 months (1
to 4). Seven other patients underwent surgery within 9 months (7
to 14) for an abnormal exercise test during follow-up (insuffi-
cient rise in blood pressure in 5 or dyspnea in 2).
Other Indications for Valve Replacement
Aortic valve replacement was necessitated by the develop-
ment of symptoms in 37 patients within 10 months (7 to 16)
(dyspnea, n32; angina pectoris, n3 including 1 patient
with associated dyspnea; syncope, n2). Four patients (aged
67 years [65 to 73]; 3 women; peak aortic-jet velocity, 4.3 m/s
[4.0 to 4.4]; serum BNP, 38 pg/mL [36 to 48]) underwent
valve replacement within 3 months (1 to 6) after enrollment,
without symptom or positive exercise test. Surgery was
performed at the discretion of the referring physician in 3
cases, whereas the fourth patient was a 31-year-old woman
with severe AS who wanted to schedule pregnancy. Data
from these 4 latter patients were censored at the time of valve
replacement.
Predictors of Outcome/Building of the Risk Score
Variables associated with the 24-month end point by univari-
able and multivariable analysis are given in Table 2. Accord-
ing to multivariable analysis, 3 parameters were independent
predictors of outcome: female sex, serum BNP, and peak
aortic-jet velocity at baseline. For each individual patient, a
risk score was calculated according to the following formula:
Score[peak velocity (m/s)2](natural logarithm of
BNP1.5)1.5 (if female sex). Of note, there were no
threshold values for the continuous variables included in the
model (Figures I and II in the online-only Data Supplement).
Kaplan–Meier analysis of symptom-free survival according
to the score quartiles in the development cohort is shown in
Figure 1.
Characteristics and Outcomes in the
Validation Cohort
The validation cohort consisted of 107 consecutive patients
with the following baseline characteristics: age, 71 years (66
to 78); 42 women (39%); peak aortic-jet velocity, 4.1 m/s (3.7
to 4.6); aortic valve area, 0.8 cm
2 (0.7 to 0.9); mean pressure
gradient, 42 mm Hg (34 to 49); serum BNP, 59 pg/mL (33 to
113). The suspected origin of AS was calcification of a
3-leaflet valve (n93), bicuspid aortic valve (n12), or
rheumatic disease (n2). Events occurred in 56 patients
within 11 months (7 to 16), including 5 deaths, 41 valve
replacements, and 10 patients who developed symptoms (3
refused surgery, and 7 were on the waiting list at the time of
last follow-up). The median follow-up duration in the vali-
Table 1. Characteristics of the 104 Patients Prospectively Followed in the Development Cohort, According
to the 24-Month End Point
Characteristic*
Whole Group
(n104)
Remained Asymptomatic
(n42)
End Point Within
24 Months (n62) P
Age, y 72 63–77	 70 53–77	 74 65–78	 0.16
Female sex, n (%) 35 (34) 9 (21) 26 (42) 0.03
Serum BNP, pg/mL 58 30–111	 30 14–64	 83 47–165	 0.0001
BNP at first follow-up, pg/mL 66 32–173	 36 16–71	 161 64–242	 0.0001
Creatinine, mol/L 96 84–109	 97 85–106	 94 83–116	 0.97
Aortic valve anatomy 0.002
Three-leaflet valve, n (%) 75 (72) 23 (55) 52 (84)
Bicuspid aortic valve, n (%) 22 (21) 13 (31) 9 (15)
Calcification score 3 to 4, n (%) 72 (69) 24 (57) 48 (77) 0.01
Peak velocity, m/s 4.1 3.5–4.4	 3.6 3.2–4.0	 4.3 3.9–4.6	 0.0001
Progression in peak velocity, m/s per year 0.3 0.0–0.5	 0.2 0.0–0.4	 0.4 0.1–0.6	 0.27
Mean pressure gradient, mm Hg 40 31–50	 33 24–40	 47 36–55	 0.0001
Valve area, cm2 0.9 0.8–1.1	 1.1 1.0–1.3	 0.8 0.7–1.0	 0.0001
Indexed area, cm
2/m
2 0.5 0.4–0.6	 0.6 0.5–0.7	 0.5 0.4–0.5	 0.0001
LV end-diastolic diameter, mm 51 47–53	 51 48–52	 50 47–53	 0.67
LV end-systolic diameter, mm 29 27–32	 29 26–32	 29 27–33	 0.50
Interventricular septum (diastole), mm 12 11–13	 12 11–13	 12 11–13	 0.48
LV posterior wall (diastole), mm 12 11–13	 12 10–13	 12 11–13	 0.24
LV ejection fraction, % 67 62–72	 68 65–72	 66 60–70	 0.08
Known coronary artery disease, n (%) 23 (22) 10 (24) 13 (21) 0.87
Diabetes mellitus, n (%) 13 (12) 4 (10) 9 (15) 0.42
Hypertension, n (%) 58 (56) 22 (52) 36 (58) 0.48
Hypercholesterolemia, n (%) 38 (37) 16 (38) 22 (35) 0.83
Values in square brackets are quartile 1 to quartile 3.
*Characteristics are given at baseline unless indicated otherwise.
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  dation sample was 21 months. Of note, 90% of outcomes
(n50) occurred before 20 months in this group. Five
patients from the validation cohort died before surgery (Table
3), all from cardiac causes (congestive heart failure, n2;
sudden death, n2; acute pulmonary edema, n1). One patient
died postoperatively (operative mortality, 2%). Valve replace-
ment was necessitated by the development of symptoms in 29
patients within 11 months (7 to 14). The main symptoms were
dyspnea, angina pectoris, or syncope in 18, 8, and 3 patients,
respectively. In the remaining 12 patients, surgery was per-
formed for new onset of atrial fibrillation (n1), positive
exercise test (n6), or equivocal symptoms (n5). In contrast,
51 patients remained free of clinical event after 21 months (18 to
27) of follow-up. The median value of the risk score in the
validation cohort was 14.9 (13.5 to 16.5). Of note, the score
values of all 5 patients who died before surgery were in the
third and fourth score quartiles (Table 3). Kaplan–Meier
analysis of symptom-free survival according to the score
quartiles in the validation cohort is given in Figure 2. This
analysis shows a progressive decrease of midterm event-free
survival according to each score quartile, without significant
difference compared with the validation cohort.
Prognostic Value of the Score Over its Range
By pooling the development and the validation cohorts
(n211 patients), the median score value was 14.8 (13.2 to
16.3). The adverse event rate according to continuous score
values in this combined cohort is shown in Figure 3. This
figure shows a low event rate (10%) for score values 11,
with a steep linear increase between 11 and 16 a slower
increase in the high-risk range (75%) for values 16.
Score Performances in the Development and
Validation Cohorts
The area under the receiver operating characteristic curve for
the score was 0.90 (95% confidence interval, 0.84 to 0.96) in the
development cohort and 0.89 (95% confidence interval, 0.84 to
0.96) in the validation cohort, indicating a good discrimination,
with a significant improvement in both cohorts compared with
peak velocity or BNP levels when considered alone (Table 4).
Discussion
The decision to operate on asymptomatic patients with severe
AS remains a source of debate. The rationale for a wait-for-
symptom strategy is supported by the rarity of sudden death
without preceding symptoms.3,7,22 Therefore, the combined
risks of surgery and prosthesis-related events probably out-
weigh the risk of sudden death in a truly asymptomatic
patient.1,2 However, there is a risk of death while the patient
is on the waiting list for surgery7 and a risk of progressive and
eventually irreversible myocardial damage.4 Therefore, risk
stratification is clinically important.
In this study, we developed a risk score based on the 3
independent predictors of midterm outcome in a population
of asymptomatic patients with mostly severe AS. According
to this score, 80% of patients within the first quartile
remained free from events after 20 months of follow-up. In
contrast, only 7% of patients within the fourth score quartile
remained free of events after 20 months.
Independent Predictors of Outcome in
Asymptomatic AS
Our results confirm the high prognostic impact of peak
aortic-jet velocity at baseline to predict the occurrence of
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Figure 1. Kaplan–Meier analysis of symptom-free survival
according to the score quartiles in the development cohort. The
respective values for score quartiles 1 to 4 were 12.9, 14.6,
16.2, and 19.7. Numbers below each slope represent the
patients at risk at each time point.
Table 2. Predictors of Outcome in the Development Cohort by Univariable and Multivariable Analysis
Univariable Analysis Multivariable Analysis
Variable Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Female sex 2.65 (1.08–6.5) 0.03 5.21 (1.46–18.6) 0.01
Serum BNP* 4.0 (2.2–7.2) 0.0001 3.87 (1.84–8.1) 0.0001
Three-leaflet valve 4.3 (1.7–10.7) 0.002 2.34 (0.56–9.7) 0.24
Calcification score 3–4 3.1 (1.3–7.5) 0.01 2.11 (0.61–7.2) 0.23
Peak velocity† 5.4 (2.45–11.8) 0.0001 6.2 (2.1–17.9) 0.001
Transaortic mean pressure gradient‡ 1.09 (1.05–1.13) 0.0001 1.14 (0.93–1.39) 0.22
Aortic valve area§ 0.59 (0.47–0.74) 0.0001 0.86 (0.63–1.16) 0.32
Indexed valve area 0.42 (0.28–0.63) 0.0001 0.7 (0.4–1.2) 0.23
Variables are given at baseline unless indicated otherwise. CI indicates confidence interval.
*Odds ratios are expressed per log unit increase in marker levels.
†Odds ratios are expressed per 1 unit increase 2.
‡Odds ratios are expressed per 1 unit increase 10.
§Odds ratios are expressed per 0.1 increase 0.5.
Odds ratios are expressed per 0.1 increase 0.3.
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   symptoms or adverse events.6 In contrast to the findings of
Rosenhek et al,7 neither the annual rate of progression in peak
velocity nor the degree of valve calcification was indepen-
dently predictive of outcome in the present study. This might
be explained for 2 main reasons. First, because of the wider
range of velocities at the time of inclusion in this study, the
prognostic impact of baseline velocity might preclude the
effect of its annual progression. Second, the most powerful
predictor of outcome in our study (ie, serum BNP) was not
assessed by Rosenhek et al.7
In contrast to previous studies,3,5–7 we found that female
sex was independently predictive of the midterm develop-
ment of symptoms. This observation is in agreement with the
results of Hachicha et al,16 who found a higher prevalence of
women among patients with paradoxical low-flow, low-
gradient AS despite normal LV function, a condition associ-
ated with a significantly worse outcome compared with
patients with normal flow.16 In addition, Legget et al23 found
that despite similar hemodynamic severity, women with AS
reported more functional impairment, with a shorter exercise
duration and lower anaerobic threshold. This may be due to a
relatively smaller LV cavity and increased relative wall
thickness that could be associated with higher filling pres-
sures and a lower increase in cardiac output during exercise.23
Moreover, an interaction between sex and serum BNP values
has also been suggested by some other reports.24,25
Previous studies have demonstrated the relationship be-
tween BNP serum levels and the hemodynamic severity of
AS,11 the presence of symptoms,10,11 or clinical outcome.8,11
To our knowledge, this is the first prospective study demon-
strating the incremental prognostic value of BNP level over
peak aortic-jet velocity in a relatively large cohort of patients
with asymptomatic AS.
Rationale for Utilizing a Risk Score
The risk score developed in the present study is based largely
on the combination of 2 quantitative variables reflecting
hemodynamic severity at baseline at both the aortic valve and
ventricular levels. Intentionally, we sought to assess all
potential predictors available at baseline to predict midterm
outcome. The rationale for this is that some patients may
become symptomatic before the first follow-up visit; thus,
follow-up parameters would not be appropriate in this case. In
contrast to every single measurement that cannot predict the
development of symptoms, this score might better reflect the
complex interplay between the LV and the aortic valve.13
Furthermore, the good reproducibility and independent prog-
nostic value of both variables have been demonstrated previ-
ously.3,8,10,11,26 Of note, all 5 preoperative deaths from the
validation cohort were due to cardiac causes, presumably
related to AS (sudden death or heart failure). More impor-
tantly, the score values of these 5 patients were all in the third
and fourth score quartiles (n2 and 3, respectively). This
result supports the fact that earlier surgery in these high-risk
patients might have prevented some of these deaths. The
rationale for utilizing this score rather than logistic models
relies on its robustness for predicting clinical outcome and its
simplicity. For research purposes as well as for the clinician,
this score is easier to use than the sophisticated logistic
models on which it was built. Further validation on large
cohorts of patients will only require computing their baseline
characteristics including sex, peak aortic velocity, and serum
Risk Score value
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Figure 3. Observed event rate at 24 months in the combined
cohort (n211 patients) according to continuous risk score
values.
Table 3. Characteristics and Outcomes in the 5 Patients Who Died Before Surgery in the
Validation Cohort
Sex Age, y
Peak
Velocity, m/s
Serum BNP,
pg/mL Score Value
Follow-Up
Duration, mo Cause of Death
Male 84 3.4 521 16.1 9 Heart failure
Male 77 4.0 123 15.2 6 Pulmonary edema
Male 78 4.3 229 16.8 8 Heart failure
Female 68 5.6 71 19.1 13 Sudden death
Female 49 4.8 116 18.3 19 Sudden death
Event-free survival (%)
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Figure 2. Kaplan–Meier analysis of symptom-free survival
according to the score quartiles in the validation cohort. The
quartiles values of the development cohort were taken for this
analysis.
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  BNP to assess the corresponding score values against out-
come. In addition, if this validation is achieved, such a score
could be easily implemented as a risk calculator for bedside
use to stratify risk in individual patients.
Limitations of the Study
A limitation of this study might be the relatively small
number of patients included in the development cohort
compared with previous prospective studies on asymptomatic
AS.6,7 In addition, the average follow-up duration in the
validation cohort was 21 months, which is slightly shorter
than the 24-month follow-up duration on which the score was
initially developed. However, given that 90% of the outcomes
occurred before 20 months in both cohorts, we think that they
are comparable. Furthermore, our results demonstrate the
excellent discrimination and calibration of this score to
predict midterm outcome, both in the development cohort and
in an independent validation cohort. Another limitation might
be the inclusion of patients with moderate AS in the devel-
opment cohort. Of note, most of the patients in this cohort
(72%) had severe AS. Furthermore, the inclusion of patients
with moderate AS is clinically relevant, given the potential
for rapid disease progression and excess mortality in these
patients.5
Conclusions
Although further validation is needed to fit with different
healthcare systems or other techniques of measurement of
BNP, this score may already be useful in its present form to
stratify risk in patient cohorts before randomization in a
prospective study. Finally, if further validation is achieved,
this score may be useful to predict outcome in individual
patients with asymptomatic AS to select those who might
benefit from early surgery.
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CLINICAL PERSPECTIVE
The decision to operate on asymptomatic patients with severe aortic stenosis remains a source of debate. The risk of sudden
death without preceding symptoms remains a matter of concern as well as the risk of irreversible myocardial damage due
to severe left ventricular hypertrophy. In the present study, we developed a risk score based on the 3 independent predictors
of midterm outcome (ie, sex, peak aortic-jet velocity, and serum B-type natriuretic peptide) in a population of 104
consecutive patients with mostly severe aortic stenosis who were asymptomatic at baseline and prospectively followed.
This score was then validated on an independent cohort of 107 consecutive patients. According to this score, 80% of
patients within the first quartile remained free from events after 20 months of follow-up. In contrast, only 7% of patients
within the fourth score quartile remained free of events after 20 months. The rationale for utilizing this score rather than
logistic models relies on its robustness for predicting clinical outcome and its simplicity. Although further validation is
needed, this score may already be useful in its present form to stratify risk in patient cohorts before randomization in a
prospective study. Finally, if further validation is achieved, this score may be useful to predict outcome in individual
patients with asymptomatic aortic stenosis to select those who might benefit from early surgery.
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Supplemental Figure 1: Lowess smoother graph of the relationship between natural logarithm of BNP 
and 24-month endpoint (bandwidth = .8) 
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Supplemental Figure 2: Lowess smoother graph of the relationship between Peak aortic-jet velocity (m/s) 
and 24-month endpoint (bandwidth = .8) 